Since Xencor’s founding in 1997, investors have been drawn to our remarkable scientific capabilities and the solid intellectual property we have built around them. We have five antibodies in clinical development internally and with partners, including XmAb®5871 in Phase 2 for the treatment of rheumatoid arthritis and lupus; XmAb®7195 in preclinical development for the treatment of asthma; and XmAb®5574/MOR208 which has been licensed to Morphosys and is in Phase 2 for acute lymphoblastic leukemia and non-Hodgkin lymphoma. Our XmAb® antibody engineering platform enables us to make subtle changes to the structure of monoclonal antibodies resulting in dramatic product enhancement and market differentiation. Our XmAb technology fuels the growth of our internal pipeline and generates revenues through partnering and licensing.
Novo Nordisk Biotech Fund
Oxford Bioscience Partners
For more information, please contact us at email@example.com.